Araceli Biosciences and Ginkgo Bioworks ( NYSE : DNA ) announced on Thursday that they have integrated the Endeavor ® high-content imaging instrument of Araceli into Ginkgo's autonomous laboratory located in Boston, Nebula.

Araceli indicates that Endeavor is the fastest high-content imaging system in the world, capable of integrating cell imaging with real-time analysis into Nebula's existing technical framework. It provides researchers with large-scale, organized datasets necessary for training and validating AI models in drug discovery.

Nebula is built upon Ginkgo's Reconfigurable Automation Carts ( RACs ). Each RAC serves as a modular unit that integrates robotic arms, automatic sample transportation, and unified control software, allowing for the addition or rearrangement of instruments as work processes change. Ginkgo states that dozens of scientists conduct real research on over 100 RAC units at Nebula every day, submit experimental plans, and receive data the following day. Nebula can autonomously perform the work equivalent to that of multiple scientists in parallel, operating day and night, and occupies about one-third of the space required by traditional laboratory benches to accomplish the same task.

Endeavor is capable of imaging a 1536-well plate in less than four minutes and has been integrated into the system based on RAC known as Nebula. It operates in parallel with the ongoing experiments within this system. With the help of ClaireRT ™ software from Araceli, Endeavor analyzes each well while collecting images. If a well does not meet the preset standards, the system can alert the operator or Nebula, or it can stop imaging to address the issue before the experiment continues.

Araceli Biosciences President and CEO, Matt Beaudet, stated: "The next generation of AI in drug discovery requires a completely different scale of biological data. The laboratories themselves are undergoing changes. They now generate cell data, interpret what they see, and respond in real time. Ginkgo is achieving this through Nebula, while Araceli brings high-content imaging and real-time analysis on a large scale into this closed loop."

Ginkgo Bioworks, co-founder and CEO, Jason Kelly stated: "Whenever you add a first-class instrument to your independent laboratory, its value increases. With your own independent laboratory, any scientist can use Endeavor's first-class high-content imaging capabilities and seamlessly connect it to all other instruments. This is the significance of an independent laboratory: to integrate the best tools in biology into one system, run your experiments on the same software, 24/7 without interruption."

About Araceli Biosciences: Araceli Biosciences develops the world's fastest high-content imaging instruments and AI-powered laboratory AI analysis software. Its integrated solutions provide real-time cellular insights, enabling automated workflows to check quality and make decisions at every stage of the experiment, helping biotechnology and pharmaceutical organizations to scale up research and development more quickly and with greater confidence. For more information, see aracelibio.com.

About Ginkgo Bioworks: Ginkgo Bioworks develops tools that make bioengineering more accessible to everyone. The company offers autonomous laboratories that replace manual laboratory work with robots, significantly increasing scientists' productivity. Ginkgo's own autonomous laboratories are also available in the form of "cloud laboratories" through its Datapoints and Solutions contract research services. For more information, visit ginkgo.bio, or follow their social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn. Ginkgo Bioworks develops infrastructure for autonomous laboratories and bio-data generation services, aiming to make experimental science more scalable and accessible. Ginkgo Bioworks is a leading horizontal platform in the field of cell programming, providing flexible, end-to-end services to organizations in various markets including food and agriculture, pharmaceuticals, as well as industry and specialty chemicals, to address related challenges.

Ginkgo Bioworks Forward-Looking Statements: This announcement contains certain forward-looking statements in the meaning of the federal securities laws, including statements regarding collaboration capabilities and potential success, as well as those concerning Ginkgo's independent laboratory. Such forward-looking statements are typically identified by words or phrases such as "believes," "can," "expects," "potential," "anticipates," "estimates," "intends," "strategy," "future," "opportunity," "plan," "may," "should," "will," "shall," "will continue," "is likely to result in," and similar expressions. Forward-looking statements are predictions, inferences, and other statements about future events based on current expectations and assumptions, and therefore involve risks and uncertainties.There are numerous factors that could lead to significant differences between actual future events and the forward-looking statements contained in this announcement, including but not limited to: (i) our ability to achieve near-term and long-term cost savings related to the site integration plan, including the ability to terminate leases or find sub-tenants for idle facilities; (ii) fluctuations in the price of Ginkgo securities due to various factors, such as changes in the highly competitive and regulated industries in which they operate and those we plan to enter, differences in competitor performance, and changes in laws and regulations that affect Ginkgo business; (iii) our ability to execute business plans, forecasts, and other expectations, as well as to identify and realize additional business opportunities, including those related to the solutions and tools business; (iv) the risk of declining demand for synthetic biology products; (v) uncertainties regarding passive monitoring projects and demand for biosafety services; (vi) changes in the biosafety industry, including technological advancements, the emergence of new competitors, and evolution of industry demands, standards, and regulations; (vii) the outcome of any pending or potential legal proceedings regarding Ginkgo; (viii) our ability to achieve the expected returns and success of platform projects and assets; (ix) our ability to successfully develop engineered cells, bioprocesses, data packages, or other deliverables; (x) the success of customers in product development, production, or manufacturing; (xi) the inherent volatility and liquidity risk associated with holding equity in other operating companies and other non-cash consideration we may receive for services; (xii) the potential negative impact of restructuring on our business, or the failure to achieve the expected savings related to restructuring; (xiii) uncertainties regarding government budget priorities and the allocation of funds to government agencies, including the possible adverse effects of a U.S. government shutdown; (xiv) our ability to expand capacity and continue to develop autonomous laboratory capabilities (including Nebula) according to the timelines and to the extent we expect.The speed and extent to which autonomous laboratory infrastructure is being adopted and replacing manual laboratory work in the broader life sciences and industrial biotechnology markets; (2) The actual size, composition, and growth of our target markets may differ significantly from our estimates; (3) The ability to integrate autonomous laboratory platforms with third-party artificial intelligence models and other technologies, as well as the development and adoption speed of such technologies; (4) The ability to maintain and expand strategic partnerships and customer relationships, including those mentioned in this announcement. The above factors are not exhaustive. Readers should carefully consider these factors as well as other risks and uncertainties described and discussed in Form's 10-K annual report filed with the U.S. Securities and Exchange Commission on February 26, 2026, under the "Risk Factors" section, and in other documents periodically submitted to SEC. These documents list and explain other important risks and uncertainties that could lead to significant differences between actual events and results and those contained in the forward-looking statements. Forward-looking statements are only valid as of the date they are made. Readers are reminded not to rely excessively on forward-looking statements, and Ginkgo does not assume nor intend to update or revise these forward-looking statements due to new information, future events, or other reasons. Ginkgo does not guarantee that it will be able to achieve its expected objectives.

Araceli Biosciences Investor and Media Contact: [ email protected ]